BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin

Reuters

Oct 13

Oct 13 (Reuters) - MannKind Corp MNKD.O:

MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR INHALED INSULIN (AFREZZA) IN CHILDREN AND ADOLESCENTS AGED 4-17 YEARS LIVING WITH DIABETES
MANNKIND CORP - AFREZZA SBLA PDUFA DATE SET FOR MAY 29, 2026

Source text: ID:nGNX2Sl4MD

Further company coverage: MNKD.O

(Reporting by Anhata Rooprai)

((Anhata.Rooprai@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2575405780"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575405780\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575405780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575405780","market":"fut","top_or_hot":-1,"title":"BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin</title></head><body><p><span>Oct 13 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR INHALED INSULIN (AFREZZA) IN CHILDREN AND ADOLESCENTS AGED 4-17 YEARS LIVING WITH DIABETES</p></li><li><p>MANNKIND CORP - AFREZZA SBLA PDUFA DATE SET FOR MAY 29, 2026</p></li></ul><p>Source text: <span>ID:nGNX2Sl4MD</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> (Reporting by Anhata Rooprai)</p><p> ((Anhata.Rooprai@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin</title></head><body><p><span>Oct 13 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR INHALED INSULIN (AFREZZA) IN CHILDREN AND ADOLESCENTS AGED 4-17 YEARS LIVING WITH DIABETES</p></li><li><p>MANNKIND CORP - AFREZZA SBLA PDUFA DATE SET FOR MAY 29, 2026</p></li></ul><p>Source text: <span>ID:nGNX2Sl4MD</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> (Reporting by Anhata Rooprai)</p><p> ((Anhata.Rooprai@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUAB725JW:1","article_id":"2575405780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575405780","pubTimestamp":1760357329,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled InsulinOct 13 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MNKD":"曼恩凯德生物医疗","BK4584":"避孕概念"},"translate_title":"简报-Mannkind宣布美国FDA接受其吸入胰岛素sBLA审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":0.9},"content_text":"BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled InsulinOct 13 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR INHALED INSULIN (AFREZZA) IN CHILDREN AND ADOLESCENTS AGED 4-17 YEARS LIVING WITH DIABETESMANNKIND CORP - AFREZZA SBLA PDUFA DATE SET FOR MAY 29, 2026Source text: ID:nGNX2Sl4MDFurther company coverage: MNKD.O (Reporting by Anhata Rooprai) ((Anhata.Rooprai@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}